Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 413-416

  Nos, Carlos ^a   Sastre Garriga, Jaume ^a   Borràs, Cecília ^a   Río, Jordi ^a   Tintoré, Mar ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

6 methylprednisolone; Clinically isolated syndrome; Expanded Disability Status Scale; Multiple sclerosis; Relapsing remitting

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL RECORD; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; OPEN STUDY; PREDICTION; RATING SCALE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344571037     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1068oa     Document Type: Article

References (15)

1. Busaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-42.
2. Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Malt Scler 2000; 6: 267-73.
3. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998; 65: 362-65.
4. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
5. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
6. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations. Neurology 1986; 36: 238-43.
7. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16.
8. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
9. Barnes D, Hughes RAC, Morris RW, Wade-Jones O, Brown P, Britton T et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-906.
10. Montalban X, Nos C. Treatment of relapses: update on steroids, mode of action, optimal route and dosage. In Kappos L, Johnson K, Kesselring J, Radü EW eds. Multiple sclerosis: tissue destruction and repair. London, UK: Martin Dunitz, 2001: 257-65.
11. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guideline for research protocols. Ann Neurol 1983; 13: 227-31.
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
14. Lienert C, Lechner-Scott J, Müller U, Kappos L. Reliability of EDSS and FS-score rating can be improved by standardised training. Mult Scler 2002; 8: S33.
15. Montalban X, Tintore M, Rio J, Galan I, Godina A. Interobserver variability in the evaluation of functional systems and Kurtzke expanded disability status scale in a multiple sclerosis patient. Rev Neurol 1996; 24: 630-32.